PUBLISHER: DelveInsight | PRODUCT CODE: 1226575
PUBLISHER: DelveInsight | PRODUCT CODE: 1226575
"Opdualag (nivolumab and relatlimab) Drug Insight and Market Forecast - 2035" report provides comprehensive insights about Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies in the 7MM. A detailed picture of the Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2035 is provided in this report along with a detailed description of the Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies . The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Opdualag (nivolumab and relatlimab) market forecast, analysis for LAG-3 Next-generation Immunotherapies in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in LAG-3 Next-generation Immunotherapies.
Relatlimab is a LAG-3-blocking antibody that binds to LAG-3 on T cells, restoring the effector function of exhausted T cells. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone. Relatlimab (in combination with nivolumab) is the first LAG-3-blocking antibody to demonstrate a benefit in a Phase III study. It is the third checkpoint inhibitor (along with anti-PD-1 and anti-CTLA-4) for Bristol Myers Squibb. When relatlimab binds to LAG-3 on T cells, this process essentially releases those brakes and stimulates T cells to attack cancer cells. This way, the immune system is again able to work as intended against cancer, reducing tumor growth.
In September 2022, the European Commission (EC) approved the fixed-dose combination of Opdualag (nivolumab and relatlimab) for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 and older with tumor cell PD-L1 expression < 1%.
In March 2022, the US Food and Drug Administration approved the first LAG-3-blocking antibody combination, Opdualag (nivolumab and relatlimab), as a treatment for patients with unresectable or metastatic melanoma.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Opdualag (nivolumab and relatlimab) Analytical Perspective by DelveInsight
This report provides a detailed market assessment of Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2035.
The report provides the clinical trials information of Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions